Gene therapy reverses complete congenital night blindness in mice, improving vision

A new preclinical study suggests that gene augmentation therapy may restore sight in a severe form of inherited night blindness. The work, reported in Gene Therapy, targets complete congenital stationary night blindness (cCSNB), a disorder in which the retinal circuitry fails to generate reliable visual responses from birth. In mouse models, treatment improved both retinal function and visual performance, offering a promising blueprint for future human therapies.

The researchers focused on augmenting gene activity to compensate for the underlying molecular defect driving defective photoreceptor signaling. Rather than attempting to edit the genome directly, the approach delivers functional genetic instructions to retinal cells, aiming to re-establish healthier visual transduction. This strategy is designed for conditions where disease-causing pathways can be partially rescued by restoring protein expression levels.

Using viral delivery, the team administered a therapeutic vector into the eyes of affected mice. After treatment, they monitored retinal function with electrophysiological assays that quantify how well retinal neurons respond to light. The results showed a measurable shift toward more normal response patterns, indicating that the treated retinas regained function rather than merely delaying degeneration.

Beyond electrophysiology, the study assessed visual acuity using behavioral and/or functional vision readouts. Improved performance suggested that molecular and cellular gains translated into practical gains in how the animals detect and resolve visual signals under experimental conditions. Importantly, the benefits were consistent with a rescue of retinal processing rather than isolated changes at the level of gene expression.

The findings also emphasize the importance of timing and targeting. Successful retinal rescue often depends on delivering the vector to the relevant cell types and achieving sufficient expression early enough to influence network behavior. While this work remains in mice, it provides evidence that the therapeutic window and delivery route can be optimized for cCSNB.

A key technical takeaway is that gene augmentation can potentially correct “wiring” problems in retinal signaling by restoring the biochemical inputs that govern photoreceptor activity. When that input is strengthened, downstream retinal circuits can produce responses closer to those seen in healthier animals, improving both sensitivity and signal fidelity.

The authors frame their results as encouraging proof-of-concept for treating complete cCSNB, where current options are limited. Future steps will likely include deeper characterization of long-term safety, expression stability, and dose-response relationships, as well as exploration of how closely mouse retinal physiology maps to human disease.

If these translational hurdles are met, viral gene augmentation could become a targeted therapy for inherited retinal disorders that primarily disrupt retinal function from the outset. For now, the study delivers a rare and hopeful message: in a model of complete congenital blindness, the retina can still be functionally recovered.